You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARP

Showing 1 - 25 of 685
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

Recruiting
  • Neuroendocrine Tumors
  • Peptide Receptor Radionuclide Therapy
  • Rotterdam, South Holland, Netherlands
    Erasmus MC
May 19, 2023

Advanced Solid Tumor Trial (CVL218)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Oct 9, 2023

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body

Recruiting
  • Sarcoma
  • +2 more
  • Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University, School of Medici
Oct 3, 2023

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Recruiting
  • Ovarian Carcinoma
  • Biospecimen Collection
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 5, 2023

Ovarian Cancer, Drug Related Tumor/Cancer Trial (secondary cytoreductive surgery, chemo)

Not yet recruiting
  • Ovarian Cancer
  • Drug Related Neoplasm/Cancer
  • (no location specified)
Jan 28, 2023

Ovarian Cancer Trial (JPI-547)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 24, 2022

Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])

Not yet recruiting
  • Acute Myeloid Leukemia
  • NK cells
  • Talazoparib 1 MG [Talzenna]
  • (no location specified)
Jan 9, 2023

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting
  • Triple Negative Metastatic Breast Cancer
  • +3 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • +3 more
  • Brussels, Belgium
  • +3 more
Dec 19, 2022

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Ovarian Cancer Trial in Madrid (Exercise and dietary recommendations)

Not yet recruiting
  • Ovarian Cancer
  • Exercise and dietary recommendations
  • Madrid, Spain
  • +3 more
Nov 15, 2023

Cytotoxic Chemotherapy and PARP Inhibition on Genomic Contexture

Recruiting
  • Ovarian Cancer
    • Athens, Greece
      Adamantia Nikolaidi
    Aug 9, 2022

    Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

    Active, not recruiting
    • Ovarian Neoplasms
    • +2 more
    • KU-0059436 (AZD2281)(PARP inhibitor)
    • Brussels, Belgium
    • +4 more
    Dec 19, 2022

    Lung Cancer Trial in Tianjin (PD-1 inhibitor, PARP inhibitor)

    Recruiting
    • Lung Cancer
    • PD-1 inhibitor
    • PARP inhibitor
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    May 23, 2022

    Pheochromocytoma, Paraganglioma Trial in Philadelphia ([18F]FluorThanatrace ([18F]FTT))

    Not yet recruiting
    • Pheochromocytoma
    • Paraganglioma
    • [18F]FluorThanatrace ([18F]FTT)
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Dec 1, 2022

    Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

    Not yet recruiting
    • Breast Cancer
    • +7 more
    • (no location specified)
    Sep 26, 2023

    Brain Metastases Trial in Houston (Niraparib, Dostarlimab)

    Not yet recruiting
    • Brain Metastases
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 17, 2023

    HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

    Recruiting
    • HRD Cancer
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Prostate Cancer Trial in Philadelphia ([18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1)

    Active, not recruiting
    • Prostate Cancer
    • [18F]FluorThanatrace
    • Poly(ADP Ribose) Polymerase 1
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    May 12, 2022

    Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

    Terminated
    • Ovarian Neoplasms
    • +3 more
    • AK112 low dose
    • +2 more
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    Oct 8, 2022

    Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

    Recruiting
    • Recurrent Fallopian Tube Carcinoma
    • +2 more
    • Boston, Massachusetts
    • +1 more
    Jan 12, 2023

    Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • (no location specified)
    Aug 8, 2022

    Head and Neck Squamous Cell Carcinoma Trial in Brescia (Niraparib)

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • Brescia, Italy
      Asst Degli Spedali Civili Di Brescia
    Aug 3, 2022